Georgetown announces phase II clinical trial of nilotinib for Parkinsonâs disease
Georgetown University Medical Center News Mar 02, 2017
Georgetown University Medical Center (GUMC) announced the launch of a phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with ParkinsonÂs disease.
GUMC is recruiting volunteers for the study in collaboration with its clinical partner, MedStar Georgetown University Hospital.
The clinical trial is a phase II, randomized, double–blind, placebo–controlled study designed to evaluate the safety and tolerability of low doses of nilotinib, the efficacy on disease biomarkers, and clinical outcomes in people with mid–stage ParkinsonÂs disease. Fernando Pagan, MD, medical director of the GUMC Translational Neurotherapeutics Program and director of the Movement Disorders Clinic at MedStar Georgetown University Hospital will serve as principal investigator on this study.
As part of the year–long random ascending dose trial, a third of the participants will receive 150mg of nilotinib, another third will receive 300mg of nilotinib and the final third will receive a placebo. Clinical outcomes will be assessed at six and 12 months and compared to assessments at the start of the trial. A one–year open–label extension trial, in which all participants will be randomized to 150mg or 300mg nilotinib, is also planned upon completion of the placebo–controlled trial to evaluate nilotinibÂs long–term effects.
The clinical trial follows a proof of concept study conducted at Georgetown (published July 11, 2016 in the Journal of ParkinsonÂs Disease) providing molecular evidence that nilotinib significantly increased brain dopamine and reduced toxic proteins linked to disease progression in ParkinsonÂs disease or dementia with Lewy bodies. Twelve participants were enrolled in the initial study; one patient withdrew due to an adverse event. Researchers say the drug appeared to be safe and well tolerated in the remaining 11 participants who completed the study.
ÂThe early proof of concept study conducted in 2015 and published in 2016 provided encouraging results, but we wonÂt know the exact effects of nilotinib on ParkinsonÂs disease until larger trials like this new one are complete, says Pagan.
ÂI am pleased to offer this study to my patients, which demonstrates the importance of teaming ParkinsonÂs care with academic research. Only through clinical trials will we be able to move the field forward so that we can offer better treatments to our patients in the future, he adds.
Nilotinib is approved by the U.S. Food and Drug Administration at much higher doses for the treatment of chronic myeloid leukemia (CML). In 2016, the U.S. Food and Drug Administration reviewed GeorgetownÂs investigational new drug application (IND) for the nilotinib study in ParkinsonÂs disease and informed GUMC investigators that the trial could proceed.
The ParkinsonÂs study and the recently announced AlzheimerÂs clinical trial with nilotinib build on research from the GUMC Translational Neurotherapeutics Program led by Charbel Moussa, MB, PhD. He and his colleagues are examining tyrosine kinase inhibitors, like nilotinib, in the treatment of neurodegenerative diseases. Tyrosine kinases appear to play a role in neurodegeneration, protein clearance and inflammation.
Go to Original
GUMC is recruiting volunteers for the study in collaboration with its clinical partner, MedStar Georgetown University Hospital.
The clinical trial is a phase II, randomized, double–blind, placebo–controlled study designed to evaluate the safety and tolerability of low doses of nilotinib, the efficacy on disease biomarkers, and clinical outcomes in people with mid–stage ParkinsonÂs disease. Fernando Pagan, MD, medical director of the GUMC Translational Neurotherapeutics Program and director of the Movement Disorders Clinic at MedStar Georgetown University Hospital will serve as principal investigator on this study.
As part of the year–long random ascending dose trial, a third of the participants will receive 150mg of nilotinib, another third will receive 300mg of nilotinib and the final third will receive a placebo. Clinical outcomes will be assessed at six and 12 months and compared to assessments at the start of the trial. A one–year open–label extension trial, in which all participants will be randomized to 150mg or 300mg nilotinib, is also planned upon completion of the placebo–controlled trial to evaluate nilotinibÂs long–term effects.
The clinical trial follows a proof of concept study conducted at Georgetown (published July 11, 2016 in the Journal of ParkinsonÂs Disease) providing molecular evidence that nilotinib significantly increased brain dopamine and reduced toxic proteins linked to disease progression in ParkinsonÂs disease or dementia with Lewy bodies. Twelve participants were enrolled in the initial study; one patient withdrew due to an adverse event. Researchers say the drug appeared to be safe and well tolerated in the remaining 11 participants who completed the study.
ÂThe early proof of concept study conducted in 2015 and published in 2016 provided encouraging results, but we wonÂt know the exact effects of nilotinib on ParkinsonÂs disease until larger trials like this new one are complete, says Pagan.
ÂI am pleased to offer this study to my patients, which demonstrates the importance of teaming ParkinsonÂs care with academic research. Only through clinical trials will we be able to move the field forward so that we can offer better treatments to our patients in the future, he adds.
Nilotinib is approved by the U.S. Food and Drug Administration at much higher doses for the treatment of chronic myeloid leukemia (CML). In 2016, the U.S. Food and Drug Administration reviewed GeorgetownÂs investigational new drug application (IND) for the nilotinib study in ParkinsonÂs disease and informed GUMC investigators that the trial could proceed.
The ParkinsonÂs study and the recently announced AlzheimerÂs clinical trial with nilotinib build on research from the GUMC Translational Neurotherapeutics Program led by Charbel Moussa, MB, PhD. He and his colleagues are examining tyrosine kinase inhibitors, like nilotinib, in the treatment of neurodegenerative diseases. Tyrosine kinases appear to play a role in neurodegeneration, protein clearance and inflammation.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
